Gilead Sciences's Revenue
- Gilead Sciences's annual revenue was $29.44 B in fiscal year 2025. The annual revenue increased $689.00 M from $28.75 B (in 2024) to $29.44 B (in 2025), representing a 2.40% year-over-year growth.
- Gilead Sciences's quarterly revenue was $7.93 B in the quarter ending Dec 2025. The quarterly revenue increased $356.00 M from $7.57 B (in Q4: Sept 2024) to $7.93 B (in Q4: Sept 2025), representing a 4.70% year-over-year growth.
- The highest annual revenue for Gilead Sciences was $30.39 B in fiscal year 2016.
- The lowest annual revenue was $22.13 B in fiscal year 2018.
- The average revenue was $26.57 B.
- Revenue is the amount of money generated by a business from sales of its goods or services. Refer to our glossary for more details, examples, and formulas.
Over the past 10 years (2016 - 2025):
Learn more about Gilead Sciences's Revenue by Segment and Revenue by Region.
Check out competitors to Gilead Sciences in a side-by-side comparison.
Explore additional financial metrics for Gilead Sciences.
Definition of Revenue :
Gilead Sciences's Revenue Trend
| 2015 | 32639000000.00 |
|---|---|
| 2016 | 30390000000.00 |
| 2017 | 26107000000.00 |
| 2018 | 22127000000.00 |
| 2019 | 22449000000.00 |
| 2020 | 24689000000.00 |
| 2021 | 27305000000.00 |
| 2022 | 27281000000.00 |
| 2023 | 27116000000.00 |
| 2024 | 28754000000.00 |
| 2025 | 29443000000.00 |
| Mar 2016 | 7794000000.00 |
|---|---|
| Jun 2016 | 7776000000.00 |
| Sep 2016 | 7500000000.00 |
| Dec 2016 | 7320000000.00 |
| Mar 2017 | 6505000000.00 |
| Jun 2017 | 7141000000.00 |
| Sep 2017 | 6512000000.00 |
| Dec 2017 | 5949000000.00 |
| Mar 2018 | 5088000000.00 |
| Jun 2018 | 5648000000.00 |
| Sep 2018 | 5596000000.00 |
| Dec 2018 | 5795000000.00 |
| Mar 2019 | 5281000000.00 |
| Jun 2019 | 5685000000.00 |
| Sep 2019 | 5604000000.00 |
| Dec 2019 | 5879000000.00 |
| Mar 2020 | 5548000000.00 |
| Jun 2020 | 5143000000.00 |
| Sep 2020 | 6577000000.00 |
| Dec 2020 | 7421000000.00 |
| Mar 2021 | 6423000000.00 |
| Jun 2021 | 6217000000.00 |
| Sep 2021 | 7421000000.00 |
| Dec 2021 | 7244000000.00 |
| Mar 2022 | 6590000000.00 |
| Jun 2022 | 6260000000.00 |
| Sep 2022 | 7042000000.00 |
| Dec 2022 | 7389000000.00 |
| Mar 2023 | 6352000000.00 |
| Jun 2023 | 6599000000.00 |
| Sep 2023 | 7050000000.00 |
| Dec 2023 | 7114000000.00 |
| Mar 2024 | 6686000000.00 |
| Jun 2024 | 6953000000.00 |
| Sep 2024 | 7545000000.00 |
| Dec 2024 | 7569000000.00 |
| Mar 2025 | 6667000000.00 |
| Jun 2025 | 7081000000.00 |
| Sep 2025 | 7769000000.00 |
| Dec 2025 | 7925000000.00 |
2025
Gilead Sciences's annual revenue was $29.44 B in fiscal year 2025.
Gilead Sciences's quarterly revenue was $6.67 B(Q1: Mar 2025), $7.08 B(Q2: Jun 2025), $7.77 B(Q3: Sep 2025), $7.93 B(Q4: Dec 2025) in fiscal year 2025.
2024
Gilead Sciences's annual revenue was $28.75 B in fiscal year 2024.
Gilead Sciences's quarterly revenue was $6.69 B(Q1: Mar 2024), $6.95 B(Q2: Jun 2024), $7.55 B(Q3: Sep 2024), $7.57 B(Q4: Dec 2024) in fiscal year 2024.
2023
Gilead Sciences's annual revenue was $27.12 B in fiscal year 2023.
Gilead Sciences's quarterly revenue was $6.35 B(Q1: Mar 2023), $6.60 B(Q2: Jun 2023), $7.05 B(Q3: Sep 2023), $7.11 B(Q4: Dec 2023) in fiscal year 2023.
2022
Gilead Sciences's annual revenue was $27.28 B in fiscal year 2022.
Gilead Sciences's quarterly revenue was $6.59 B(Q1: Mar 2022), $6.26 B(Q2: Jun 2022), $7.04 B(Q3: Sep 2022), $7.39 B(Q4: Dec 2022) in fiscal year 2022.
2021
Gilead Sciences's annual revenue was $27.31 B in fiscal year 2021.
Gilead Sciences's quarterly revenue was $6.42 B(Q1: Mar 2021), $6.22 B(Q2: Jun 2021), $7.42 B(Q3: Sep 2021), $7.24 B(Q4: Dec 2021) in fiscal year 2021.
2020
Gilead Sciences's annual revenue was $24.69 B in fiscal year 2020.
Gilead Sciences's quarterly revenue was $5.55 B(Q1: Mar 2020), $5.14 B(Q2: Jun 2020), $6.58 B(Q3: Sep 2020), $7.42 B(Q4: Dec 2020) in fiscal year 2020.
2019
Gilead Sciences's annual revenue was $22.45 B in fiscal year 2019.
Gilead Sciences's quarterly revenue was $5.28 B(Q1: Mar 2019), $5.69 B(Q2: Jun 2019), $5.60 B(Q3: Sep 2019), $5.88 B(Q4: Dec 2019) in fiscal year 2019.
2018
Gilead Sciences's annual revenue was $22.13 B in fiscal year 2018.
Gilead Sciences's quarterly revenue was $5.09 B(Q1: Mar 2018), $5.65 B(Q2: Jun 2018), $5.60 B(Q3: Sep 2018), $5.80 B(Q4: Dec 2018) in fiscal year 2018.
2017
Gilead Sciences's annual revenue was $26.11 B in fiscal year 2017.
Gilead Sciences's quarterly revenue was $6.51 B(Q1: Mar 2017), $7.14 B(Q2: Jun 2017), $6.51 B(Q3: Sep 2017), $5.95 B(Q4: Dec 2017) in fiscal year 2017.
2016
Gilead Sciences's annual revenue was $30.39 B in fiscal year 2016.
Gilead Sciences's quarterly revenue was $7.79 B(Q1: Mar 2016), $7.78 B(Q2: Jun 2016), $7.50 B(Q3: Sep 2016), $7.32 B(Q4: Dec 2016) in fiscal year 2016.
Gilead Sciences's Revenue (Year-over-Year Change)
| 2015 | 0 |
|---|---|
| 2016 | -6.89 |
| 2017 | -14.09 |
| 2018 | -15.24 |
| 2019 | +1.46 |
| 2020 | +9.98 |
| 2021 | +10.60 |
| 2022 | -0.09 |
| 2023 | -0.60 |
| 2024 | +6.04 |
| 2025 | +2.40 |
| Q1: Mar 16 | 2.63 |
|---|---|
| Q2: Jun 16 | -5.68 |
| Q3: Sep 16 | -9.58 |
| Q4: Dec 16 | -13.94 |
| Q1: Mar 17 | -16.54 |
| Q2: Jun 17 | -8.17 |
| Q3: Sep 17 | -13.17 |
| Q4: Dec 17 | -18.73 |
| Q1: Mar 18 | -21.78 |
| Q2: Jun 18 | -20.91 |
| Q3: Sep 18 | -14.07 |
| Q4: Dec 18 | -2.59 |
| Q1: Mar 19 | 3.79 |
| Q2: Jun 19 | 0.66 |
| Q3: Sep 19 | 0.14 |
| Q4: Dec 19 | 1.45 |
| Q1: Mar 20 | 5.06 |
| Q2: Jun 20 | -9.53 |
| Q3: Sep 20 | 17.36 |
| Q4: Dec 20 | 26.23 |
| Q1: Mar 21 | 15.77 |
| Q2: Jun 21 | 20.88 |
| Q3: Sep 21 | 12.83 |
| Q4: Dec 21 | -2.39 |
| Q1: Mar 22 | 2.60 |
| Q2: Jun 22 | 0.69 |
| Q3: Sep 22 | -5.11 |
| Q4: Dec 22 | 2.00 |
| Q1: Mar 23 | -3.61 |
| Q2: Jun 23 | 5.42 |
| Q3: Sep 23 | 0.11 |
| Q4: Dec 23 | -3.72 |
| Q1: Mar 24 | 5.26 |
| Q2: Jun 24 | 5.36 |
| Q3: Sep 24 | 7.02 |
| Q4: Dec 24 | 6.40 |
| Q1: Mar 25 | -0.28 |
| Q2: Jun 25 | 1.84 |
| Q3: Sep 25 | 2.97 |
| Q4: Dec 25 | 4.70 |
2025
Gilead Sciences’s annual revenue increased +2.40% during fiscal year 2025 compared to 2024. It represents a growth of $689.00 M from $28.75 B (in 2024) to $29.44 B (in 2025).
2024
Gilead Sciences’s annual revenue increased +6.04% during fiscal year 2024 compared to 2023. It represents a growth of $1.64 B from $27.12 B (in 2023) to $28.75 B (in 2024).
2023
Gilead Sciences’s annual revenue decreased -0.60% during fiscal year 2023 compared to 2022. It represents a decline of -$165.00 M from $27.28 B (in 2022) to $27.12 B (in 2023).
2022
Gilead Sciences’s annual revenue decreased -0.09% during fiscal year 2022 compared to 2021. It represents a decline of -$24.00 M from $27.31 B (in 2021) to $27.28 B (in 2022).
2021
Gilead Sciences’s annual revenue increased +10.60% during fiscal year 2021 compared to 2020. It represents a growth of $2.62 B from $24.69 B (in 2020) to $27.31 B (in 2021).
2020
Gilead Sciences’s annual revenue increased +9.98% during fiscal year 2020 compared to 2019. It represents a growth of $2.24 B from $22.45 B (in 2019) to $24.69 B (in 2020).
2019
Gilead Sciences’s annual revenue increased +1.46% during fiscal year 2019 compared to 2018. It represents a growth of $322.00 M from $22.13 B (in 2018) to $22.45 B (in 2019).
2018
Gilead Sciences’s annual revenue decreased -15.24% during fiscal year 2018 compared to 2017. It represents a decline of -$3.98 B from $26.11 B (in 2017) to $22.13 B (in 2018).
2017
Gilead Sciences’s annual revenue decreased -14.09% during fiscal year 2017 compared to 2016. It represents a decline of -$4.28 B from $30.39 B (in 2016) to $26.11 B (in 2017).
2016
Gilead Sciences’s annual revenue decreased -6.89% during fiscal year 2016 compared to 2015. It represents a decline of -$2.25 B from $32.64 B (in 2015) to $30.39 B (in 2016).
Summary Table (Annual)
| Period | Revenue | Year-over-Year Change |
|---|---|---|
| 2025 | $29.44 B | +2.40% |
| 2024 | $28.75 B | +6.04% |
| 2023 | $27.12 B | -0.60% |
| 2022 | $27.28 B | -0.09% |
| 2021 | $27.31 B | +10.60% |
| 2020 | $24.69 B | +9.98% |
| 2019 | $22.45 B | +1.46% |
| 2018 | $22.13 B | -15.24% |
| 2017 | $26.11 B | -14.09% |
| 2016 | $30.39 B | -6.89% |
Summary Table (Quarterly)
| Period | Revenue | Year-over-Year Change |
|---|---|---|
| Q4: Dec 25 | $7.93 B | 4.70% |
| Q3: Sep 25 | $7.77 B | 2.97% |
| Q2: Jun 25 | $7.08 B | 1.84% |
| Q1: Mar 25 | $6.67 B | -0.28% |
| Q4: Dec 24 | $7.57 B | 6.40% |
| Q3: Sep 24 | $7.55 B | 7.02% |
| Q2: Jun 24 | $6.95 B | 5.36% |
| Q1: Mar 24 | $6.69 B | 5.26% |
| Q4: Dec 23 | $7.11 B | -3.72% |
| Q3: Sep 23 | $7.05 B | 0.11% |
| Q2: Jun 23 | $6.60 B | 5.42% |
| Q1: Mar 23 | $6.35 B | -3.61% |
| Q4: Dec 22 | $7.39 B | 2.00% |
| Q3: Sep 22 | $7.04 B | -5.11% |
| Q2: Jun 22 | $6.26 B | 0.69% |
| Q1: Mar 22 | $6.59 B | 2.60% |
| Q4: Dec 21 | $7.24 B | -2.39% |
| Q3: Sep 21 | $7.42 B | 12.83% |
| Q2: Jun 21 | $6.22 B | 20.88% |
| Q1: Mar 21 | $6.42 B | 15.77% |
| Q4: Dec 20 | $7.42 B | 26.23% |
| Q3: Sep 20 | $6.58 B | 17.36% |
| Q2: Jun 20 | $5.14 B | -9.53% |
| Q1: Mar 20 | $5.55 B | 5.06% |
| Q4: Dec 19 | $5.88 B | 1.45% |
| Q3: Sep 19 | $5.60 B | 0.14% |
| Q2: Jun 19 | $5.69 B | 0.66% |
| Q1: Mar 19 | $5.28 B | 3.79% |
| Q4: Dec 18 | $5.80 B | -2.59% |
| Q3: Sep 18 | $5.60 B | -14.07% |
| Q2: Jun 18 | $5.65 B | -20.91% |
| Q1: Mar 18 | $5.09 B | -21.78% |
| Q4: Dec 17 | $5.95 B | -18.73% |
| Q3: Sep 17 | $6.51 B | -13.17% |
| Q2: Jun 17 | $7.14 B | -8.17% |
| Q1: Mar 17 | $6.51 B | -16.54% |
| Q4: Dec 16 | $7.32 B | -13.94% |
| Q3: Sep 16 | $7.50 B | -9.58% |
| Q2: Jun 16 | $7.78 B | -5.68% |
| Q1: Mar 16 | $7.79 B | 2.63% |
